|
ESDR Online Abstract Submission Guidelines |
|
|
|
Please submit your abstract for the ESDR 37th Annual Meeting 2007 via the ESDR website before the submission deadline of 31 May 2007. Below you will find the instructions for on-line submission of abstracts.
General Rules for Submission
Only one paper or poster may be read or presented by the same author at the meeting, although a presenter may be coauthor of any number of papers. The material should not have been published or presented at any European meeting prior to the date of presentation. It is permissible, however, to have presented the material previously at a regional meeting and to have had it published in abstract form in a publication associated with one of these meetings.
Abstract submissions may only be made through the website. Support is available by contacting the ESDR Office (
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
)
Abstract Destination
All abstracts submitted to the ESDR Meeting will be considered for oral presentation at the main ESDR meeting, except those marked for poster presentation by the author.
If your abstract is not selected for oral presentation at the ESDR meeting, you may be invited to give an oral presentation at a satellite meeting of ESDR 2007 such as the EIS Satellite Meeting or the EDEN Meeting. In this case you will be contacted directly by the organisers of the satellite meeting.
Abstract Publication
Abstracts will be published in the August 2007 issue of the Journal of Investigative Dermatology and on the ESDR Website.
Submission Deadlne
The abstract submission system will close at midnight (CET) on 31 May 2007. Late submissions will not be accepted.
Late-Breaking Abstracts
The ESDR is not accepting late-breaking abstracts for the 2007 meeting.
Abstract Submission - Detailed Instructions
Please complete the steps in the on-line abstract submission procedure on the ESDR website adhering to the instructions given there. To submit the abstract text, you must copy your text into the form provided. Do not exceed 300 words.
Abstracts must conform to the following standards:
Do not exceed 300 words (Title and Text). Overly long abstracts may be edited.
Do not use graphics or tables.
Do NOT put author names or affiliations in the abstract text. This will help to ensure that your abstract is reviewed fairly.
The entire abstract (abstract title and text) must be typed single-spaced throughout the document. Leave no space between the title and body of the abstract or between paragraphs.
The title must be brief and indicate clearly the nature of the investigation. The title should be upper and lowercase letters. Abbreviations must not be used in the title.
Do not use capitals or underline for emphasis in the text. Use the standard Symbol font for Greek and math symbols.
The abstract body should be organised as follows:
(a) a sentence describing the purpose of the study;
(b) a statement of experimental design or method used;
(c) a summary of results, presented in sufficient detail to support the conclusion; and
(d) a statement of conclusions reached.
It is not satisfactory to state "The results will be discussed..." or "Other data will be presented." Do not use subtitles, e.g., methods, results, etc. within the body of the abstract. Failure to follow this format will result in a low priority score and may cause disqualification of your abstract.
Nonproprietary (generic) names should be given the first time a drug is mentioned in the body of the abstract and should be written in small letters. The first letter of a proprietary name is always capitalized, e.g., cyproheptadine (Periactin).
Do not mention support of work by a research grant.
Do not include references. These will be deleted.
|
|
Last Updated ( Friday, 14 August 2009 )
|
